Tumor Homing Reactive Oxygen Species Nanoparticle for Enhanced Cancer Therapy
- Authors
- Cho, Hyeon-Yeol; Mavi, Ahmet; Chueng, Sy-Tsong Dean; Pongkulapa, Thanapat; Pasquale, Nicholas; Rabie, Hudifah; Han, Jiyou; Kim, Jong Hoon; Kim, Tae-Hyung; Choi, Jeong-Woo; Lee, Ki-Bum
- Issue Date
- Jul-2019
- Publisher
- American Chemical Society
- Keywords
- cancer therapy; magnetic core-shell nanoparticles; nanotechnology; reactive species; tumor targeting
- Citation
- ACS Applied Materials and Interfaces, v.11, no.27, pp 23900 - 23918
- Pages
- 19
- Journal Title
- ACS Applied Materials and Interfaces
- Volume
- 11
- Number
- 27
- Start Page
- 23900
- End Page
- 23918
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/33068
- DOI
- 10.1021/acsami.9b07483
- ISSN
- 1944-8244
1944-8252
- Abstract
- Multifunctional nanoparticles that carry chemotherapeutic agents can be innovative anticancer therapeutic options owing to their tumor-targeting ability and high drug-loading capacity. However, the nonspecific release of toxic DNA-intercalating anticancer drugs from the nanoparticles has significant side effects on healthy cells surrounding the tumors. Herein, we report a tumor homing reactive oxygen species nanoparticle (THoR-NP) platform that is highly effective and selective for ablating malignant tumors. Sodium nitroprusside (SNP) and diethyldithiocarbamate (DDC) were selected as an exogenous reactive oxygen species (ROS) generator and a superoxide dismutase 1 inhibitor, respectively. DDC-loaded THoR-NP, in combination with SNP treatment, eliminated multiple cancer cell lines effectively by the generation of peroxynitrite in the cells (>95% cell death), as compared to control drug treatments of the same concentration of DDC or SNP alone (0% cell death). Moreover, the magnetic core (ZnFe2O4) of the THoR-NP can specifically ablate tumor cells (breast cancer cells) via magnetic hyperthermia, in conjunction with DDC, even in the absence of any exogenous RS supplements. Finally, by incorporating iRGD peptide moieties in the THoR-NP, integrin-enriched cancer cells (malignant tumors, MDA-MB-231) were effectively and selectively killed, as opposed to nonmetastatic tumors (MCF-7), as confirmed in a mouse xenograft model. Hence, our strategy of using nanoparticles embedded with ROS-scavenger-inhibitor with an exogenous ROS supplement is highly selective and effective cancer therapy. © 2019 American Chemical Society.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of ICT Engineering > School of Integrative Engineering > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/33068)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.